Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
- 1 March 2008
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 134 (3), 688-695
- https://doi.org/10.1053/j.gastro.2007.12.012
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetesPharmacoepidemiology and Drug Safety, 2007
- Safety issues and prospects for future generations of PPAR modulatorsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Coronary heart disease outcomes in patients receiving antidiabetic agentsPharmacoepidemiology and Drug Safety, 2007
- Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- PPAR as a new therapeutic target in inflammatory bowel diseasesGut, 2006
- Peroxisome proliferator activated receptor in colonic epithelial cells protects against experimental inflammatory bowel diseaseGut, 2005
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in CanadaDigestive Diseases and Sciences, 1987